These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 22726454)

  • 1. Immunophenotype classification and therapeutic outcomes of Chinese primary gastrointestinal diffuse large B-cell lymphoma.
    Zhang Z; Shen Y; Shen D; Ni X
    BMC Gastroenterol; 2012 Jun; 12():77. PubMed ID: 22726454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between immunophenotype classification and clinicopathological features in chinese patients with primary gastric diffuse large B-cell lymphoma.
    Zizhen Z; Hui C; Yanying S; Danping S; Jiahua L; Chao H; Xingzhi N
    Pathol Oncol Res; 2013 Apr; 19(2):317-22. PubMed ID: 23239192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Primary gastrointestinal diffuse large B-cell lymphoma: an immunohistochemical and prognostic study of 90 cases].
    Lin L; Min M; Bi CF; Wang XQ; Luo TY; Zhao S; Zhang WY; Liu WP
    Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):220-6. PubMed ID: 21615994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era.
    Seki R; Ohshima K; Fujisaki T; Uike N; Kawano F; Gondo H; Makino S; Eto T; Moriuchi Y; Taguchi F; Kamimura T; Tsuda H; Ogawa R; Shimoda K; Yamashita K; Suzuki K; Suzushima H; Tsukazaki K; Higuchi M; Utsunomiya A; Iwahashi M; Imamura Y; Tamura K; Suzumiya J; Yoshida M; Abe Y; Matsumoto T; Okamura T
    Cancer Sci; 2009 Oct; 100(10):1842-7. PubMed ID: 19656156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. R-CHOP regimen can significantly decrease the risk of disease relapse and progression in patients with non-germinal center B-cell subtype diffuse large B-cell lymphoma.
    He XH; Li B; Yang S; Lu N; Zhang X; Zou SM; Li YX; Song YW; Zheng S; Dong M; Zhou SY; Yang JL; Liu P; Zhang CG; Qin Y; Feng FY; Shi YK
    Chin J Cancer; 2012 Jun; 31(6):306-14. PubMed ID: 22640627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma.
    Xia Y; Li ZM; Shi YX; Xia ZJ; Jiang WQ; Huang HQ
    Ai Zheng; 2009 Feb; 28(2):146-9. PubMed ID: 19550126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.
    Li ZM; Huang JJ; Xia Y; Zhu YJ; Zhao W; Wei WX; Jiang WQ; Lin TY; Huang HQ; Guan ZZ
    Eur J Haematol; 2012 Jun; 88(6):510-7. PubMed ID: 22413767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
    Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
    J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of R-CHOP or CHOP regimen for germinal center and nongerminal center subtypes of diffuse large B-cell lymphoma of Chinese patients.
    Huang Y; Ye S; Cao Y; Li Z; Huang J; Huang H; Cai M; Luo R; Lin T
    ScientificWorldJournal; 2012; 2012():897178. PubMed ID: 23213304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Subgrouping and outcome prediction of diffuse large B-cell lymphoma by immunohistochemistry].
    Ye ZY; Cao YB; Lin TY; Lin HL
    Zhonghua Bing Li Xue Za Zhi; 2007 Oct; 36(10):654-9. PubMed ID: 18194597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of germinal center B-cell-like and non-germinal center B-cell-like subtypes of bone marrow involvement in patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Cho MC; Chung Y; Jang S; Park CJ; Chi HS; Huh J; Suh C; Shim H
    Medicine (Baltimore); 2018 Nov; 97(45):e13046. PubMed ID: 30407302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Nodal versus extranodal diffuse large B-cell lymphoma: comparison of clinicopathologic features, immunophenotype and prognosis].
    Lu JB; Li XQ; Zhang PH; Zhou XY; Zhang TM; Li XM; Zhu XZ
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):470-3. PubMed ID: 17845761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical significance of bcl-2 protein expression and classification algorithm in diffuse large B-cell lymphoma].
    Li M; Liu CL; Wang XY; Xue XM; Gao ZF
    Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):813-7. PubMed ID: 23324229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.
    van Imhoff GW; Boerma EJ; van der Holt B; Schuuring E; Verdonck LF; Kluin-Nelemans HC; Kluin PM
    J Clin Oncol; 2006 Sep; 24(25):4135-42. PubMed ID: 16943530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
    Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE
    J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diffuse large B-cell lymphoma of testis: a clinicopathologic and immunophenotypic study of 58 cases].
    Yang ZR; Bi CF; Zhang WY; Yang QP; Liu WP
    Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):589-92. PubMed ID: 24314243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulated expression of Dicer1 predicts inferior survival in primary gastrointestinal diffuse large B-cell lymphoma treated with CHOP-like regimen and rituximab.
    Zhao H; Zhang L; Guo S; Yuan T; Xia B; Qu F; Zhang L; Zhang Y
    Med Oncol; 2014 Oct; 31(10):206. PubMed ID: 25195038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
    Pedersen MØ; Gang AO; Brown P; Pedersen M; Knudsen H; Nielsen SL; Poulsen T; Wirenfeldt Klausen T; Høgdall E; Nørgaard P
    PLoS One; 2017; 12(10):e0186983. PubMed ID: 29088292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunophenotypes and prognosis of diffuse large B-cell lymphoma: a study of 500 cases].
    Luo DL; Liu YH; Zhuang HG; Li L; Xu FP; Zhang F; Luo XL; Xu J
    Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):235-9. PubMed ID: 21615996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.